Universal Influenza Virus Vaccines: Need for Clinical Trials

Overview

Journal Nat Immunol

Date 2013 Dec 20

PMID 24352315

Citations 42

Authors

Florian Krammer

Peter Palese

Affiliations

Soon will be listed here.

Citing Articles

Nanovaccines Displaying the Influenza Virus Hemagglutinin in an Inverted Orientation Elicit an Enhanced Stalk-Directed Antibody Response.

Frey S, Carreno J, Bielak D, Arsiwala A, Altomare C, Varner C Adv Healthc Mater. 2023; 12(13):e2202729.

PMID: 36689343 PMC: 10386890. DOI: 10.1002/adhm.202202729.

A Single Vaccination of Chimeric Bivalent Virus-Like Particle Vaccine Confers Protection Against H9N2 and H3N2 Avian Influenza in Commercial Broilers and Allows a Strategy of Differentiating Infected from Vaccinated Animals.

Sun Y, Li Z, Zhang P, Han J, Di H, Qin J Front Immunol. 2022; 13:902515.

PMID: 35874682 PMC: 9304867. DOI: 10.3389/fimmu.2022.902515.

A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice.

Bliss C, Freyn A, Caniels T, Leyva-Grado V, Nachbagauer R, Sun W Mol Ther. 2022; 30(5):2024-2047.

PMID: 34999208 PMC: 9092311. DOI: 10.1016/j.ymthe.2022.01.011.

Single Dose of Bivalent H5 and H7 Influenza Virus-Like Particle Protects Chickens Against Highly Pathogenic H5N1 and H7N9 Avian Influenza Viruses.

Hu J, Peng P, Li J, Zhang Q, Li R, Wang X Front Vet Sci. 2021; 8:774630.

PMID: 34859093 PMC: 8632145. DOI: 10.3389/fvets.2021.774630.

Administration of Multivalent Influenza Virus Recombinant Hemagglutinin Vaccine in Combination-Adjuvant Elicits Broad Reactivity Beyond the Vaccine Components.

Hernandez-Davies J, Felgner J, Strohmeier S, Pone E, Jain A, Jan S Front Immunol. 2021; 12:692151.

PMID: 34335601 PMC: 8318558. DOI: 10.3389/fimmu.2021.692151.

References

Wei C, Yassine H, McTamney P, Gall J, Whittle J, Boyington J . Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure. Sci Transl Med. 2012; 4(147):147ra114. DOI: 10.1126/scitranslmed.3004273. View

Sui J, Hwang W, Perez S, Wei G, Aird D, Chen L . Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol. 2009; 16(3):265-73. PMC: 2692245. DOI: 10.1038/nsmb.1566. View

Margine I, Krammer F, Hai R, Heaton N, Tan G, Andrews S . Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J Virol. 2013; 87(19):10435-46. PMC: 3807421. DOI: 10.1128/JVI.01715-13. View

Palese P, Wang T . Why do influenza virus subtypes die out? A hypothesis. mBio. 2011; 2(5). PMC: 3163940. DOI: 10.1128/mBio.00150-11. View

Corti D, Voss J, Gamblin S, Codoni G, Macagno A, Jarrossay D . A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011; 333(6044):850-6. DOI: 10.1126/science.1205669. View

Wei C, Boyington J, McTamney P, Kong W, Pearce M, Xu L . Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science. 2010; 329(5995):1060-4. DOI: 10.1126/science.1192517. View

Cowling B, Ng S, Ma E, Fang V, So H, Wai W . Protective efficacy against pandemic influenza of seasonal influenza vaccination in children in Hong Kong: a randomized controlled trial. Clin Infect Dis. 2012; 55(5):695-702. DOI: 10.1093/cid/cis518. View

Pica N, Hai R, Krammer F, Wang T, Maamary J, Eggink D . Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci U S A. 2012; 109(7):2573-8. PMC: 3289326. DOI: 10.1073/pnas.1200039109. View

Margine I, Hai R, Albrecht R, Obermoser G, Harrod A, Banchereau J . H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice. J Virol. 2013; 87(8):4728-37. PMC: 3624338. DOI: 10.1128/JVI.03509-12. View

10.

Garcia-Garcia L, Valdespino-Gomez J, Lazcano-Ponce E, Jimenez-Corona A, Higuera-Iglesias A, Cruz-Hervert P . Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City. BMJ. 2009; 339:b3928. PMC: 2758337. DOI: 10.1136/bmj.b3928. View

11.

de Jong J, Beyer W, Palache A, Rimmelzwaan G, Osterhaus A . Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol. 2000; 61(1):94-9. View

12.

Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W . Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013; 368(20):1888-97. DOI: 10.1056/NEJMoa1304459. View

13.

Heinen P, Rijsewijk F, de Boer-Luijtze E, Bianchi A . Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J Gen Virol. 2002; 83(Pt 8):1851-1859. DOI: 10.1099/0022-1317-83-8-1851. View

14.

Lillie P, Berthoud T, Powell T, Lambe T, Mullarkey C, Spencer A . Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis. 2012; 55(1):19-25. PMC: 3369564. DOI: 10.1093/cid/cis327. View

15.

Khurana S, Loving C, Manischewitz J, King L, Gauger P, Henningson J . Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci Transl Med. 2013; 5(200):200ra114. DOI: 10.1126/scitranslmed.3006366. View

16.

. Interim adjusted estimates of seasonal influenza vaccine effectiveness - United States, February 2013. MMWR Morb Mortal Wkly Rep. 2013; 62(7):119-23. PMC: 4604884. View

17.

Vincent A, Lager K, Janke B, Gramer M, Richt J . Failure of protection and enhanced pneumonia with a US H1N2 swine influenza virus in pigs vaccinated with an inactivated classical swine H1N1 vaccine. Vet Microbiol. 2007; 126(4):310-23. DOI: 10.1016/j.vetmic.2007.07.011. View

18.

Couch R, Decker W, Utama B, Atmar R, Nino D, Feng J . Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans. PLoS One. 2012; 7(12):e50830. PMC: 3519816. DOI: 10.1371/journal.pone.0050830. View

19.

Wrammert J, Smith K, Miller J, Langley W, Kokko K, Larsen C . Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature. 2008; 453(7195):667-71. PMC: 2515609. DOI: 10.1038/nature06890. View

20.

Miller M, Tsibane T, Krammer F, Hai R, Rahmat S, Basler C . 1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. J Infect Dis. 2012; 207(1):98-105. PMC: 3523798. DOI: 10.1093/infdis/jis652. View